Disappearance of factor VIII antibodies upon frequent administration of factor VIII.

E P Mauser-Bunschoten, G Roosendaal, M Bruin, P J van Dijken
{"title":"Disappearance of factor VIII antibodies upon frequent administration of factor VIII.","authors":"E P Mauser-Bunschoten,&nbsp;G Roosendaal,&nbsp;M Bruin,&nbsp;P J van Dijken","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>20 haemophilia patients known to have antibodies against F VIII for at least more than three years were treated on a regular base with 25 U/kg b.w. F VIII every other day. All 5 patients with previous maximal anti F VIII antibody levels between 5 and 60 BU/ml showed a decrease of antibody level and normal F VIII recovery within 1-2 months. From 12 patients with previous antibody levels above 60 BU/ml, 8 showed a disappearance of antibodies within 2-26 months. In 3 patients in whom no previous highest inhibitor level was known, one was treated successfully. Another group of 6 young patients in whom an inhibitor against F VIII had just (less than 3 months) developed, was treated with F VIII as soon as an inhibitor was detected. The dose infused was 25 U/kg b.w. F VIII twice weekly. In 5 patients this regimen was successful within 1-7 months. In the 6th patient the dosage was increased to every other day. One year after the beginning of therapy no inhibitor was detectable. So our results show that regular administration of F VIII in intermediate or low dose can lead to rapid disappearance of anti F VIII antibodies especially in patients with moderate inhibitor levels.</p>","PeriodicalId":75853,"journal":{"name":"Folia haematologica (Leipzig, Germany : 1928)","volume":"117 4","pages":"533-7"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia haematologica (Leipzig, Germany : 1928)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

20 haemophilia patients known to have antibodies against F VIII for at least more than three years were treated on a regular base with 25 U/kg b.w. F VIII every other day. All 5 patients with previous maximal anti F VIII antibody levels between 5 and 60 BU/ml showed a decrease of antibody level and normal F VIII recovery within 1-2 months. From 12 patients with previous antibody levels above 60 BU/ml, 8 showed a disappearance of antibodies within 2-26 months. In 3 patients in whom no previous highest inhibitor level was known, one was treated successfully. Another group of 6 young patients in whom an inhibitor against F VIII had just (less than 3 months) developed, was treated with F VIII as soon as an inhibitor was detected. The dose infused was 25 U/kg b.w. F VIII twice weekly. In 5 patients this regimen was successful within 1-7 months. In the 6th patient the dosage was increased to every other day. One year after the beginning of therapy no inhibitor was detectable. So our results show that regular administration of F VIII in intermediate or low dose can lead to rapid disappearance of anti F VIII antibodies especially in patients with moderate inhibitor levels.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
频繁服用因子VIII后因子VIII抗体消失。
20例已知有fviii抗体至少3年以上的血友病患者每隔一天接受25 U/kg体重fviii的常规治疗。5例既往最高抗fviii抗体水平在5 ~ 60 BU/ml之间的患者均在1 ~ 2个月内抗体水平下降,fviii恢复正常。既往抗体水平高于60 BU/ml的12例患者中,8例抗体在2-26个月内消失。在3例既往无最高抑制剂水平的患者中,1例治疗成功。另一组6名年轻患者的F - VIII抑制剂刚刚(不到3个月)出现,一旦检测到抑制剂就立即接受F - VIII治疗。注射剂量为25 U/kg b.w.f VIII,每周2次。在5例患者中,该方案在1-7个月内成功。在第6例患者中,剂量增加到每隔一天。治疗开始一年后,未检测到任何抑制剂。因此,我们的研究结果表明,定期给予中剂量或低剂量的fviii可导致抗fviii抗体迅速消失,特别是在中等抑制剂水平的患者中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Bone marrow and spleen morphology following haemolytic anaemia in adult laboratory rats of various age groups. Oxidative stress of red blood cells stored for transfusion use. Beta-glucuronidase activity in neutrophils of patients with malignancies. Effect of recombinant human alpha interferon (INF) on chronic granulocytic leukaemia (CGL) clonogenic growth of bone marrow haematopoietic progenitors. Effect of recombinant human alpha interferon (INF) and antilymphocyte globulin (ALG) on normal and aplastic anaemia haematopoietic progenitor cell growth.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1